{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-290707","form_type":"8-K","ticker":"INAB","cik":"0001740279","company_name":"IN8BIO, INC.","filed_at":"2023-12-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.277068+00:00","generated_at":"2026-06-07T16:18:35.712300+00:00","sec_items":["5.02","5.03","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"IN8bio appoints Dr. Corinne Epperly to Board, adopts amended bylaws","bullets":["Board expanded to 8 directors; Dr. Epperly appointed as Class II director effective Dec 6, 2023, term through 2026 annual meeting.","Dr. Epperly to serve on Compensation and Science & Technology Committees; former COO of Cargo Therapeutics and SVP at Iovance.","Bylaws amended to comply with universal proxy rules (Rule 14a-19), enhance stockholder nominee disclosures, and adopt DGCL updates.","Non-employee director compensation policy updated Dec 5, 2023: annual cash retainer $40k, initial option grant 54,800 shares, annual grant 27,400 shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-290707","json":"https://secwatch.observer/filing/0001193125-23-290707.json","markdown":"https://secwatch.observer/filing/0001193125-23-290707.md","text":"https://secwatch.observer/filing/0001193125-23-290707.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1740279/000119312523290707/0001193125-23-290707-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1740279/000119312523290707/d634027d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T16:18:35.712300+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"20d4252ebc","claim":"Corinne Epperly was appointed as Class II Director at IN8BIO, INC..","evidence_excerpt":"appointed Corinne Epperly, M.D., as a Class II director of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1740279/000119312523290707/0001193125-23-290707-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II Director"}],"fact_type":"executive_change"},{"claim_id":"58a597611608601c83b3143e28de1f3b92923494","claim":"IN8BIO, INC.: Board approved and adopted Second Amended and Restated Bylaws with changes addressing universal proxy rules, advance notice requirements, and other updates (effective 2023-12-06).","evidence_excerpt":"On December 6, 2023, the Board approved and adopted the Second Amended and Restated Bylaws of the Company (the “Amended Bylaws”), which became effective immediately.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1740279/000119312523290707/0001193125-23-290707-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2023-12-06"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}